J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market
FDA approved Johnson & Johnson's IL-23 blocker guselkumab July 13; the drug will be priced at an annual wholesale acquisition cost of $58,100, roughly in line with the currently marketed IL-17 blocker Cosentyx.
You may also be interested in...
Novartis stresses long-term safety database for Cosentyx – with five years' worth of data in three indications – psoriasis, psoriatic arthritis and ankylosing spondylitis.
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Recent launches Tremfya and Erleada are viewed as catalysts for continuing growth, along with ambitious plans to add indications for Imbruvica, Darzalex and Stelara.